Abstract
The brain of patients with Alzheimer disease (AD) showed the evidence of reduced expression of insulin and neuronal insulin receptors, as compared with those of age-matched controls. This event gradually and certainly leads to a breakdown of the entire insulin-signaling pathway, which manifests insulin resistance. This in turn affects brain metabolism and cognitive functions, which are the bestdocumented abnormalities in AD. These observations led Dr. de la Monte and her colleagues to suggest that AD is actually a neuroendocrine disorder that resembles type 2 diabetes mellitus. The truth would be more complex with understanding the role of low-density lipoprotein receptor-related protein 1, Aβ derived diffusible ligands, and advanced glycation end products. However, now it known as “brain diabetes” and is called type 3 diabetes mellitus (T3DM). This review provides an overview of “brain diabetes” focusing on the reason why the phenomenon is called T3DM.
Keywords: Alzheimer disease, Diabetes mellitus, Insulin, Type 2 diabetes mellitus, Type 3 diabetes mellitus.
Current Topics in Medicinal Chemistry
Title:Type 3 Diabetes Mellitus: A Novel Implication of Alzheimers Disease
Volume: 17 Issue: 12
Author(s): Jerzy Leszek, Elzbieta Trypka, Vadim V. Tarasov, Ghulam Md Ashraf and Gjumrakch Aliev
Affiliation:
Keywords: Alzheimer disease, Diabetes mellitus, Insulin, Type 2 diabetes mellitus, Type 3 diabetes mellitus.
Abstract: The brain of patients with Alzheimer disease (AD) showed the evidence of reduced expression of insulin and neuronal insulin receptors, as compared with those of age-matched controls. This event gradually and certainly leads to a breakdown of the entire insulin-signaling pathway, which manifests insulin resistance. This in turn affects brain metabolism and cognitive functions, which are the bestdocumented abnormalities in AD. These observations led Dr. de la Monte and her colleagues to suggest that AD is actually a neuroendocrine disorder that resembles type 2 diabetes mellitus. The truth would be more complex with understanding the role of low-density lipoprotein receptor-related protein 1, Aβ derived diffusible ligands, and advanced glycation end products. However, now it known as “brain diabetes” and is called type 3 diabetes mellitus (T3DM). This review provides an overview of “brain diabetes” focusing on the reason why the phenomenon is called T3DM.
Export Options
About this article
Cite this article as:
Leszek Jerzy, Trypka Elzbieta, Tarasov V. Vadim, Ashraf Md Ghulam and Aliev Gjumrakch, Type 3 Diabetes Mellitus: A Novel Implication of Alzheimers Disease, Current Topics in Medicinal Chemistry 2017; 17 (12) . https://dx.doi.org/10.2174/1568026617666170103163403
DOI https://dx.doi.org/10.2174/1568026617666170103163403 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Peptides: An Alternative Approach for the Treatment of Diabetes Mellitus
Current Drug Therapy Detection of Glucose in Human Serum Based on Silicon Dot Probe
Current Analytical Chemistry Treatment Strategies Against Diabetic Foot Ulcer: Success so Far and the Road Ahead
Current Diabetes Reviews Statins and Vulnerable Plaque
Current Pharmaceutical Design Current and Emerging Treatments for Metastatic Renal Cell Carcinoma
Current Cancer Drug Targets Patent Selections :
Recent Patents on Cardiovascular Drug Discovery Synthesis, Characterization, Biological Evaluation and Docking of Coumarin Coupled Thiazolidinedione Derivatives and its Bioisosteres as PPARγ Agonists
Medicinal Chemistry Cardiovascular Disease Risk of Type 2 Diabetes Mellitus and Metabolic Syndrome: Focus on Aggressive Management of Dyslipidemia
Current Diabetes Reviews Characteristics Other than the Diagnostic Criteria Associated with Metabolic Syndrome: An Overview
Current Vascular Pharmacology Growth Hormone and Insulin-Like Growth Factor-I as an Endocrine Axis in Alzheimers Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Microvascular Endothelial Dysfunction in Obesity and Hypertension
Current Pharmaceutical Design Nucleic Acid-Based Aptamers: Applications, Development and Clinical Trials
Current Medicinal Chemistry Specific Nutritional Needs for Children. Are Children Small Adults?
Current Nutrition & Food Science Masked Hypertension and Diabetes
Current Hypertension Reviews Morphology of Atherosclerotic Plaque: Its Feature by Imaging Study
Current Pharmaceutical Design EDITORIAL (Thematic Issue: Retinal Neurodegeneration in the Course of Diabetes: Neuroprotection as a Potential Treatment Target)
Current Neuropharmacology Interventions to Reduce Cardiovascular Risk in Children with Type 1 Diabetes
Current Diabetes Reviews Improving Health Care for Children with Chronic Conditions: Toward a “Wholistic” Approach
Current Pediatric Reviews Network Insights into the Genes Regulated by Hepatocyte Nuclear Factor 4 in Response to Drug Induced Perturbations: A Review
Current Drug Discovery Technologies Lipid Management and Peripheral Arterial Disease
Current Drug Targets